ChiCTR-TRC-12002072
正在进行
/
/
/
2012-04-04
/
/
women undergoing IVF-ET cycles
Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles
Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles
The effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles
随机平行对照
其它
RCT
Double-blind
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong
/
60
/
1990-01-01
1990-01-01
/
1. History of 2 episodes of poor ovarian response (less than 3 mature follicles on ovulatory dose of hCG or less than 3 mature oocytes retrieved) despite maximal stimulation; or 2. Patients fulfill two out of three of the following features: I.Age >=40 or any other risk factors: (1)History of ovarian surgery; (2)History of salpingectomy; (3)History of chemotherapy; (4)Present of ovarian endometrioma.；
登录查看1. Body mass index more than 30kg/m2; 2. Absent of one ovary; 3. History of polycystic ovarian disease; 4. Present of uterine abnormalities; 5. Present of endocrine/metabolic/autoimmune disease; 6. Incompetence or refuse for informed consent.；
登录查看Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong
/
约印创投2025-01-16
求实药社2025-01-16
Genhouse2025-01-16
IPHASE2025-01-16
动脉网2025-01-16
动脉网-最新2025-01-16
药明康德2025-01-16
药明康德2025-01-16
再鼎医药2025-01-16
Rimonci2025-01-15
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
